| [1] |
ROLFO C, MACK P C, SCAGLIOTTI G V, et al. Liquid biopsy for advanced non-small cell lung cancer(NSCLC):a statement paper from the IASLC[J]. J Thorac Oncol, 2018, 13(9):1248-1268.
DOI
URL
|
| [2] |
CUI S, YE L, WANG H, et al. Use of SuperARMS EGFR mutation detection kit to detect EGFR in plasma cell-free DNA of patients with lung adenocarcinoma[J]. Clin Lung Cancer, 2018, 19(3):e313-e322.
DOI
URL
|
| [3] |
WU W, CAO Z, ZHANG W, et al. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients[J]. Diagn Pathol, 2020, 15(1):9.
DOI
|
| [4] |
WU L R, CHEN S X, WU Y, et al. Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification[J]. Nat Biomed Eng, 2017, 1:714-723.
DOI
PMID
|
| [5] |
SKRONSKI M, CHOROSTOWSKA-WYNIMKO J, SZCZEPULSKA E, et al. Reliable detection of rare mutations in EGFR gene codon L858 by PNA-LNA PCR clamp in non-small cell lung cancer[J]. Adv Exp Med Biol, 2013, 756:321-331.
|
| [6] |
AGGARWAL C, ROLFO C D, OXNARD G R, et al. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice[J]. Nat Rev Clin Oncol, 2021, 18(1):56-62.
DOI
|
| [7] |
EVRARD S M, TARANCHON-CLERMONT E, ROUQUETTE I, et al. Multicenter evaluation of the fully automated PCR-based idylla EGFR mutation assay on formalin-fixed,paraffin-embedded tissue of human lung cancer[J]. J Mol Diagn, 2019, 21(6):1010-1024.
DOI
URL
|
| [8] |
KOBAYASHI Y, MITSUDOMI T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy[J]. Cancer Sci, 2016, 107(9):1179-1186.
DOI
URL
|
| [9] |
KOBAYASHI Y, TOGASHI Y, YATABE Y, et al. EGFR exon 18 mutations in lung cancer:molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs[J]. Clin Cancer Res, 2015, 21(23):5305-5313.
DOI
URL
|
| [10] |
TRUINI A, STARRETT J H, STEWART T, et al. The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma[J]. Clin Cancer Res, 2019, 25(21):6382-6391.
DOI
URL
|
| [11] |
WEI Q, ZHANG J, CHEN D, et al. Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation[J]. Lung Cancer, 2020, 148:175-176.
DOI
URL
|
| [12] |
FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations[EB/OL]. (2018-01-16)[2022-06-01]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr.
|
| [13] |
QIN Y, JIAN H, TONG X, et al. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors[J]. Mol Oncol, 2020, 14(8):1695-1704.
DOI
PMID
|
| [14] |
SAXON J A, SHOLL L M, JÄNNE P A. EGFR L858M/L861Q cis mutations confer selective sensitivity to afatinib[J]. J Thorac Oncol, 2017, 12(5):884-889.
DOI
PMID
|
| [15] |
BEJJANKI H, BISHNOI R, REISMAN D. Novel mutation pair L858M/L861Q caused resistance to both first- and third-generation EGFR inhibitors,but was found to be sensitive to the combination of lapatinib and erbitux[J]. J Thorac Oncol, 2017, 12(10):e169-e170.
DOI
URL
|
)
